In part 2 of the phase I PROFILE 1001 trial for ROS1-rearranged NSCLC patients, two patients with ALK-rearrangements who received crizotinib 250 mg orally twice daily showed a significant response. The gene discussed is ALK; the disease is non-small cell lung carcinoma.